Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival

Table 1 Clinical characteristics of all patients in the programmed cell death-1/programmed death-ligand 1 and cytotoxic T-lymphocyte antigen 4 groups

Characteristic	PD-1/PD-L1, n = 605	CTLA-4, n = 56	P value
Age, yr, median (range)	69 (22-87)	65 (21-85)	0.039
Sex, n (%)			0.228
Male	419 (69.3)	34 (60.7)
Female	186 (30.7)	22 (39.3)
BMI, kg/m2	21.3 (12.0-37.0)	21.6 (13.9-43.0)	0.532
ECOG PS, n (%)			0.073
0-1	534 (88.3)	54 (96.4)
2-3	71 (11.7)	2 (3.6)
Cancer type, n (%)
NSCLC	241 (39.8)	0 (0.0)
MM	110 (18.2)	39 (69.6)
RCC	52 (8.6)	17 (30.4)
GC	49 (8.1)	0 (0.0)
Others	153(25.3)	0 (0.0)
Drugs, n (%)
Nivolumab	317 (52.4)	0 (0.0)
Pembrolizumab	180 (29.8)	0 (0.0)
Atezolizumab	74 (12.2)	0 (0.0)
Durvalumab	32 (5.3)	0 (0.0)
Avelumab	2 (0.3)	0 (0.0)
Ipilimumab	0 (0.0)	28 (50.0)
Nivolumab + ipilimumab	0 (0.0)	28 (50.0)

BMI: Body mass index; CTLA-4: Cytotoxic T-lymphocyte antigen 4; ECOG PS: Eastern Cooperative Oncology Group performance status; GC: Gastric cancer; MM: Malignant melanoma; NSCLC: Non-small cell lung cancer; PD-1/PD-L1: Programmed cell death-1/programmed death-ligand 1; RCC: Renal cell carcinoma.